292 related articles for article (PubMed ID: 10080412)
21. Antianginal efficacy of carvedilol, a new beta-blocker with vasodilating action.
Jamal SM; Freedman SB; Thomson A; Carter G; Harris PJ; Kelly DT
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S141-6. PubMed ID: 2454361
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients.
Weber K; Bohmeke T; van der Does R; Taylor SH
Cardiovasc Drugs Ther; 1996 May; 10(2):113-7. PubMed ID: 8842502
[TBL] [Abstract][Full Text] [Related]
23. Anti-anginal and anti-ischemic effects of the selective beta-blocker talinolol in patients with stable angina pectoris.
Faulhaber HD; Weigmann I; Lang U; Weinsberg F; Terhaag B
Int J Clin Pharmacol Ther; 2005 Feb; 43(2):63-70. PubMed ID: 15726874
[TBL] [Abstract][Full Text] [Related]
24. Vasodilating beta-blockers in heart failure.
Raftery EB
Eur Heart J; 1995 Jul; 16 Suppl F():32-7. PubMed ID: 8521882
[TBL] [Abstract][Full Text] [Related]
25. The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers.
Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Petersen HH; Torp-Pedersen C; Riahi S; Jøns C
Europace; 2018 Feb; 20(2):301-307. PubMed ID: 28339659
[TBL] [Abstract][Full Text] [Related]
26. Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study.
Kveiborg B; Hermann TS; Major-Pedersen A; Christiansen B; Rask-Madsen C; Raunsø J; Køber L; Torp-Pedersen C; Dominguez H
Cardiovasc Diabetol; 2010 May; 9():21. PubMed ID: 20500877
[TBL] [Abstract][Full Text] [Related]
27. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J
Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705
[TBL] [Abstract][Full Text] [Related]
28. Comparison of carvedilol and atenolol for angina pectoris.
Freedman SB; Jamal SM; Harris PJ; Kelly DT
Am J Cardiol; 1987 Sep; 60(7):499-502. PubMed ID: 2888302
[TBL] [Abstract][Full Text] [Related]
29. Hemodynamic differences between metoprolol and carvedilol in hypertensive patients.
Weber K; Bohmeke T; van der Does R; Taylor SH
Am J Hypertens; 1998 May; 11(5):614-7. PubMed ID: 9633801
[TBL] [Abstract][Full Text] [Related]
30. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lubsen J; Lutiger B; Metra M; Remme WJ; Torp-Pedersen C; Scherhag A; Skene A;
Lancet; 2003 Jul; 362(9377):7-13. PubMed ID: 12853193
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET.
Cleland JG
Curr Heart Fail Rep; 2004 Jul; 1(2):82-8. PubMed ID: 16036030
[TBL] [Abstract][Full Text] [Related]
32. Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?
Doggrell SA
Expert Opin Pharmacother; 2004 Jan; 5(1):205-8. PubMed ID: 14680448
[TBL] [Abstract][Full Text] [Related]
33. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris.
Lahiri A; Rodrigues EA; Al-Khawaja I; Raftery EB
Am J Cardiol; 1987 Apr; 59(8):769-74. PubMed ID: 2881480
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of carvedilol (BM 14,190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia.
Kaski JC; Rodriguez-Plaza L; Brown J; Maseri A
Am J Cardiol; 1985 Jul; 56(1):35-40. PubMed ID: 2861738
[TBL] [Abstract][Full Text] [Related]
35. [Beta blockers for therapy of chronic heart failure].
Murakami T
Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):248-54. PubMed ID: 15768588
[No Abstract] [Full Text] [Related]
36. Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy.
Piccirillo G; Quaglione R; Nocco M; Naso C; Moisè A; Lionetti M; Di Carlo S; Marigliano V
Am J Cardiol; 2002 Nov; 90(10):1113-7. PubMed ID: 12423713
[TBL] [Abstract][Full Text] [Related]
37. How should COMET influence heart failure practice?
Adams KF
Curr Heart Fail Rep; 2004 Jul; 1(2):67-71. PubMed ID: 16036027
[TBL] [Abstract][Full Text] [Related]
38. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).
Torp-Pedersen C; Metra M; Charlesworth A; Spark P; Lukas MA; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Remme WJ; Scherhag A;
Heart; 2007 Aug; 93(8):968-73. PubMed ID: 17237130
[TBL] [Abstract][Full Text] [Related]
39. Effect of metoprolol and amlodipine on myocardial total ischaemic burden in patients with stable angina pectoris.
Klein G; Pfafferott C; Beil S; Gehring J; Niemelä M; Kendall MJ
J Clin Pharm Ther; 1997; 22(5-6):371-8. PubMed ID: 19160722
[TBL] [Abstract][Full Text] [Related]
40. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study.
Sellier P; Broustet JP
Am J Cardiovasc Drugs; 2003; 3(5):361-9. PubMed ID: 14728070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
